BlackRock Inc. - BIOXCEL THERAPEUTICS INC ownership

BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 94 filers reported holding BIOXCEL THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.86 and the average weighting 0.0%.

Quarter-by-quarter ownership
BlackRock Inc. ownership history of BIOXCEL THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$3,283,204
-64.5%
1,297,709
-6.6%
0.00%
Q2 2023$9,252,266
-63.8%
1,389,229
+1.4%
0.00%
-100.0%
Q1 2023$25,577,038
-18.6%
1,370,688
-6.3%
0.00%0.0%
Q4 2022$31,423,564
+81.7%
1,462,922
-0.0%
0.00%0.0%
Q3 2022$17,297,000
-7.9%
1,463,372
+2.8%
0.00%0.0%
Q2 2022$18,787,000
-29.9%
1,423,347
+11.1%
0.00%0.0%
Q1 2022$26,787,000
+2.2%
1,280,979
-0.7%
0.00%0.0%
Q4 2021$26,218,000
-29.0%
1,289,654
+6.0%
0.00%0.0%
Q3 2021$36,928,000
+12.2%
1,216,737
+7.4%
0.00%0.0%
Q2 2021$32,907,000
-27.7%
1,132,402
+7.4%
0.00%0.0%
Q1 2021$45,495,000
+9.4%
1,054,104
+17.1%
0.00%0.0%
Q4 2020$41,572,000
+18.3%
899,806
+11.1%
0.00%0.0%
Q3 2020$35,127,000
-8.1%
810,132
+12.4%
0.00%
-50.0%
Q2 2020$38,215,000
+242.5%
720,887
+44.4%
0.00%
+100.0%
Q1 2020$11,159,000
+90.7%
499,234
+24.6%
0.00%
Q4 2019$5,852,000
+169.4%
400,565
+29.8%
0.00%
Q3 2019$2,172,000
-33.7%
308,556
+3.1%
0.00%
Q2 2019$3,278,000
+2208.5%
299,145
+1988.0%
0.00%
Q1 2019$142,000
+140.7%
14,327
-6.4%
0.00%
Q4 2018$59,000
-50.8%
15,307
-1.8%
0.00%
Q3 2018$120,000
-12.4%
15,587
+4.2%
0.00%
Q2 2018$137,00014,9570.00%
Other shareholders
BIOXCEL THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Knoll Capital Management, LLC 60,000$151,8000.16%
XTX Topco Ltd 33,605$85,0210.02%
Beacon Pointe Advisors, LLC 301,735$763,3900.01%
AllSquare Wealth Management LLC 4,527$11,4530.01%
Virtus ETF Advisers LLC 4,646$11,7540.01%
Y-Intercept (Hong Kong) Ltd 27,553$69,7090.01%
SeaCrest Wealth Management, LLC 16,550$41,8720.01%
Hennion & Walsh Asset Management, Inc. 33,940$85,8680.01%
Cutler Group LLC / CA 4,000$500.01%
Capital Investment Advisory Services, LLC 17,991$45,5170.00%
View complete list of BIOXCEL THERAPEUTICS INC shareholders